Reading BNBX? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track BNBX free→Reading BNBX? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track BNBX free→QuarterlyIQ Insights · BNBX
Material updates from SEC filings (8-K, 10-Q, 10-K) ranked by impact, with no firehose noise.
Unregistered Sales of Equity Securities On May 28, 2026, the Company closed the transaction contemplated by the SPA and sold and issued to the Purchaser, at an offering price of $1.05 per share, 2,380,953 shares of Series B-1 Preferred Stock and Common Warrants to purchase 2,380,953 shares of Common Stock. Gross proceeds from the SPA totaled $2.5 million. On May 31, 2026, the Company entered into an Inducement Agreement with an Exchanging Holder for an exercise of Series E Warrants in an aggr…
Entry into a Material Definitive Agreement. Private Placement and Inducement Transaction On May 26, 2026, BNB Plus Corp., a Delaware corporation (the “Company”), entered into agreements to issue in one or more offerings up to an aggregate amount of $5 million (the “Aggregate Offering Amount”) of the Company’s securities in a convertible preferred equity private placement financing pursuant to: (1) a Securities Purchase Agreement (the “SPA”) with accredited investors (“Purchasers”) whereby Pur…
Unregistered Sales of Equity Securities. To the extent required by
Material Modification to Rights of Security Holders. To the extent required by
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. BNB Plus Corp. (the “Company”) received written notice dated March 20, 2026 (the “Notification Letter”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) that the Company no longer satisfies the $1.00 bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2) for continued listing on the Nasdaq Capital Market. Nasdaq Listing Rule 5550(a)(2) requires li…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On February 2, 2026, the Board of Directors (the “Board”) of BNB Plus Corp. (the “Company”) appointed James Haft to serve as a director and as a member of the Nominating Committee of the Board, effective February 2, 2026, u ntil his successor has been duly elected and qualified, or until his earlier resignation or removal . At the time of Mr. Haft’…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On January 15, 2026, Elizabeth M. Schmalz Shaheen resigned as a director of BNB Plus Corp. (the “Company”), effective immediately. Ms. Schmalz Shaheen’s resignation was not the result of any disagreement with the Company on any matter relating to the Company’s operations, policies or practices. SIGNATURES Pursuant to the requirements of the Securit…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On November 6, 2025, the Board of Directors (the “Board”) of Applied DNA Sciences, Inc. (the “Company”), upon recommendation of the Nominating Committee of the Board, appointed Joshua Kruger to serve as its Chairman and as a director. At the time of Mr. Kruger’s appointment, the Board had a vacancy as the result of the previously disclosed resignat…
Entry into a Material Definitive Agreement On November 4, 2025, Applied DNA Sciences, Inc. (the “ Company ”) entered into an At The Market Offering Agreement (the “ Agreement ”) with Lucid Capital Markets, LLC, as sales agent (the “ Agent ”), pursuant to which the Company may, from time to time, offer and sell shares of its common stock, par value $0.001 per share, with an aggregate offering price of up to $8,157,932 (the “ Shares ”) through the Agent. The offer and sale of the Shares made pu…
Other Events. On October 22, 2025, Applied DNA Sciences, Inc. (the “Company”) announced the closing of its previously announced private placement offerings in which, (i) the Company sold to certain accredited investors, at an offering price of $3.32 per share, an aggregate of 4,620,485 shares of common stock of the Company, par value $0.001 per share (the “Common Stock”), and/or prefunded warrants in lieu thereof (with such prefunded warrants having an exercise price of $0.0001 per share), an…
Costs Associated with Exit or Disposal Activities. On September 30, 2025, the Board of Directors of Applied DNA Sciences, Inc. (the “ Company ”) authorized, and its officers implemented, a restructuring plan pursuant to which the Company will reduce overall operating expenses to focus resources on its previously announced BNB-focused treasury strategy. The restructuring plan includes a reduction of the Company’s current workforce by sixteen employees, or approximately 60%. The Company estimat…
Regulation FD Disclosure. On October 6, 2025, the Company issued a press release announcing that it will change its ticker symbol on the Nasdaq Capital Market from "APDN" to "BNBX" effective at the opening of trading on Tuesday, October 7, 2025. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated by reference herein. The information in this Item 7.01, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed to be “filed” for purposes of…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On September 28, 2025, Judith Murrah informed the Company of her intention to step down from her positions as the Company’s Chief Executive Officer and President effective September 29, 2025. As described in the Initial 8-K, Ms. Murrah’s title is Strategic Transition Advisor and she will remain as Chairperson of the Company’s Board of Directors (th…
Neither this Current Report on Form 8-K nor any exhibit attached hereto is an offer to sell or the solicitation of an offer to buy shares of Common Stock or other securities of the Company.
Entry into a Material Definitive Agreement. Securities Purchase Agreement On September 29, 2025, Applied DNA Sciences, Inc., a Delaware corporation (the “Company”) entered into a securities purchase agreement (the “Cash Securities Purchase Agreement”) with certain accredited investors (the “Cash Purchasers”) pursuant to which the Company agreed to sell and issue to the Cash Purchasers in a private placement offering (the “Cash Offering”), at an offering price of $3.32 per share, an aggregate…
Other Information. In connection with the Offering and related transactions described herein, the Company is filing certain updated business description disclosure for the purpose of supplementing and updating disclosures contained in the Company’s prior public filings, including those discussed under the heading “Item 1. Business” in the Company’s Annual Report on Form 10-K for the year ended September 30, 2024, filed with the SEC on December 17, 2024. The supplemental updated business descr…
Other Events. Placement Agent Warrants In connection with the Offering, on August 10, 2025, the Company entered into an engagement agreement with the Placement Agent (the “Placement Agent Agreement”), pursuant to which the Placement Agent agreed to act as Placement Agent for the Offering. The term of the Placement Agent Agreement is ninety (90) days from September 9, 2025. If the Company closes the Offering, the term of the Placement Agent Agreement shall be extended until the earlier of (i)…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On September 28, 2025, Judith Murrah informed the Company of her intention to step down from her positions as the Company’s Chief Executive Officer and President effective September 29, 2025. As described below, Ms. Murrah’s title is Strategic Transition Advisor and she will remain as Chairperson of the Company’s Board of Directors (the “Board”) un…
Neither this Current Report on Form 8-K nor any exhibit attached hereto is an offer to sell or the solicitation of an offer to buy shares of Common Stock or other securities of the Company.
shall have the meanings set forth in the Securities Purchase Agreement, as applicable. Prior to the Closing Date, the Company was a biotechnology company focused on providing nucleic-acid production solutions for the biopharmaceutical and diagnostics industries. The Company’s technologies enabled cell-free manufacturing of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA), which are essential components for a new generation of advanced biotherapeutics, such as gene therapies, adoptive ce…
Results of Operations and Financial Condition. On August 14, 2025, Applied DNA Sciences, Inc. (the “Company”) issued a press release announcing its results of operations for the quarterly period ended June 30, 2025. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information furnished pursuant to this Item 2.02, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the…
Regulation FD Disclosure. On June 30, 2025, the Company issued a press release announcing the strategic restructuring and realignment of resources. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated by reference herein. The information in this Item 7.01, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “ Exchange Act ”), or otherwis…
Costs Associated with Exit or Disposal Activities. On June 30, 2025, Applied DNA Sciences, Inc. (the “ Company ”) announced a strategic restructuring and realignment of resources to focus exclusively on its synthetic DNA manufacturing business, LineaRx. As part of actions undertaken, the Company implemented a workforce reduction of approximately 27% of headcount and has ceased operations at Applied DNA Clinical Labs (“ ADCL ”), a business that provides molecular and genetic testing services,…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Effective June 30, 2025, Judith Murrah, the Company’s Chief Executive Officer, President and Chairperson, voluntarily agreed to a fifteen percent (15%) temporary reduction in her annual base salary in connection with the Company’s efforts to reduce its ongoing operating expenses. Ms. Murrah’s reduced annual base salary is $340,000. The reduction is…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On June 16, 2025, Dr. James A. Hayward informed Applied DNA Sciences, Inc. (the “Company”) of his intention to retire from the Company and that he will step down from his positions as Chief Executive Officer, member of the Company’s board of directors (the “Board”) and Chairman of the Board effective June 18, 2025. Dr. Hayward’s resignation is not…
General market headlines, full earnings-call transcripts, and macro and sector developments flagged when they directly affect this stock are on the way. Today this tab covers SEC filings.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.